The Sustained Virologic Response and Adverse Effects of Peg Interferon Alfa and Ribavirin in the Treatment of Patients with Chronic Hepatitis C: A Study from Iran by Shoaei, Simindokht et al.
  Novelty in Biomedicine 




The Sustained Virologic Response and Adverse Effects of Peg 
Interferon Alfa and Ribavirin in the Treatment of Patients with 














1Department of infectious disease, Clinical Research and Development Center, Imam Hossein Hospital, Shahid Beheshti university of    
   Medical science, Tehran, Iran 
2Department of infectious disease, Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical  
   Sciences, Tehran, IR Iran 
3Infectious disease and Tropical Medicine Research Center, Kerman university of medical science, Kerman, Iran 
 
Received: 06  June, 2017; Accepted: 20 Sepetember, 2017 
Abstract 
Background: Hepatitis C infection is a worldwide problem. In Iran, hepatitis C virus (HCV) infection 
prevalence is about 1-2%. A combination therapy of pegylated interferon alfa-2a and ribavirin (PEG-
IFNa/RBV) is a standard treatment, but our aim was to determine the efficacy and safety of dual PEG-
IFNa/RBV therapy in treating patients infected with HCV in Iranian context. 
Materials and Methods: This study is a cross sectional conducted among 98 HCV infected patients who were 
admitted to Labbafinezhad Hospital (Tehran, Iran) for treatment from April 2014 to September 2016. Patients 
were medicated with Peg Interferon Alfa (INFα) and Ribavirin (RBV). Lab tests were monitored through the 
study and dose modification was done. We also assessed treatment responses at the defined time points. The 
incidences of adverse events were determined either. We investigated independent predictors of sustained 
virologic response (SVR) in the participants. Finally, data were gathered and statistical analysis was completed. 
Results: Eighty-eight percent of patients were male and 11.2% were female. Mean age was 43.44 years. 
Patients were mostly male, single, with nongovernmental business and low level of education. Risk factors 
were known to be addiction with non-injectable substances and phlebotomy. Myalgia, fatigue and malaises 
were the most common complications and suicide intention was the least one. SVR was estimated 76.7%. 
AST and ALT were significantly reduced in treatment period. 
Conclusion: Peg INFα and RBV are effective in treating HCV infection. 
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Hepatitis C infection is a worldwide health problem 
with an incidence of 170 million universally
1
. 
Hepatitis C Virus (HCV) attacks principally the 
hepatocytes
2
 where it replicates and kills liver cells
3
, 
and thus HCV infected patients may possibly develop 
chronic liver disease and hepatocellular cell carcinoma 
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(HCC)
4
. A wide range of 60 to 80 percent of HCV 
infected patients shift from the acute state of hepatitis 
infection to chronic state, and then to hepatic 
steatosis
5,6
. The Center for Disease Control has found 
that HCV infection diagnosis remained 
underestimated and has recommended further 




Hepatitis infection incidence rate in Iran is about1% 
annually and it is still increasing regarding the 
changes in people’s lifestyle and addiction to 
injectable substances
7
. In 1960s, when only hepatitis 
A and hepatitis B were known, the treatment of these 
two types of hepatitis was limited to bed rest, 
nutrition, diet and symptomatic medications
8
, but 
new medications have evolved therapy and have 
saved many lives. Though, there are still several 
disadvantages of new medications, including side 
effects that sometimes interruptthe treatment. In this 
study, we aimed to assess the response to dual 
therapy with pegylated INFα and RBV, as well as 
estimating side effects in Iranian population. 
Response to therapy is characterized with an 
indicator named Sustained Virological Response 
(SVR). SVR is defined as the absence of HCV RNA 
within 6 months following therapy and is related to 





The study had a cross sectional design with a 
prospective approach. Patients' data were analyzed 
before and after intervention within 24 months. Each 
patient’s information was obtained before treatment, 
as well as 12, 24 and 48 weeks and 6 months later for 
follow up. SVR and medication side effects were 
estimated as each time ends. The study objectives 
were estimation of response to therapy during 
implementation of treatment protocol and 6 months 
later and identification of laboratory and clinical 
medication’s side effects. 
Ninety-eight patients admitted in Labbafinezhad 
Hospital for HCV infection treatment. First of all, 
approval from the institutional ethics committee was 
obtained. The study was conducted from April 2013 
to September 2014 among HCV positive patients 
attending the hospital. HCV positive patients above 
15 years of age whose HCV PCR turned positive 
within the recent year and whose lab tests consist of 
Hemoglobin (Hg) more than 12.5, Absolute 
Neutrophil Count (NAC) more than 1500 mm
3 
and 
Platelet (PLT) Count more than 80000 were included 
in the study after taking informed consent. Patients 
with comorbidities such as human immunodeficiency 
virus infection, other active liver disease, 
Hepatocellular Cell Carcinoma, untreated Diabetes, 
Malignant Neoplastic disease, severe cardiopulmonary 
disease, Retinopathy, immunodeficiency disorders, 
untreated psychological disorder and major depression 
were excluded. A detailed clinical evaluation (history 
and clinical examination) of all the recruited subjects 
was done and relevant laboratory investigations were 
accomplished in specific time intervals as mentioned. 
Patients' side effects were retrieved and documented 
after telephone call. Side effects were categorized into 
three types: life-threatening, severe, modified and 
mild. Patients must be excluded if life-threatening side 
effects were detected, and further therapy must be 
implemented to cure the possible complications. 
Modified and mild side effects were treated by dose 
reduction and administrating appropriate medications 
like antidepressant agents for treating depression. 
Our paraclinical indicator for dose modification is 
illustrated in table 1. Those patients who had 
experienced side effects were followed every two 
weeks and treatments were restarted if lab tests turned 
normal.  
All collected data were entered manually into Excel 
sheets. Statistical analysis was performed using SPSS 
software. P value was determined and p value <0.05 
was considered to be statistically significant. Mean, 
median, mode and standard deviation were also 
estimated. To investigate the independent factor 
related to SVR, a multivariate analysis was performed 
through a stepwise logistic regression analysis. 
Results 
Eighty-eight percent of patients were male and 11.2% 
were female. Mean age was 43.44 years. Patients were 
mostly male, single, with nongovernmental business 
and low level of education. Risk factors were 
addiction with non-injectable substances and 
phlebotomy. Myalgia, fatigue and malaises were the 
most common complications and suicide intention was 
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the last one. Eighty-three point seven percent of 
patients completed their therapy. The most genotype 
known was 1a. Monthly monitoring of ALT, AST, 
WBC, PMN, PLT and Hg showed no statically 
significant differences within the different periods of 
treatment. TSH was the only variable which was not 
significantly different in treatment timeline. Most 
occurrences in lab complication were neutrophilia 
and anemia. SVR was seen in 76.7%. AST and ALT 
were significantly reduced in treatment period. 
Discussion 
In medicine benefits of every treatment regimen must 
be weigh subsequently in order to determine its use in 
clinical practice. Among different medications, 
recombinant interferon α in combination with RBV 
seems to be effective for the treatment of viral 
hepatitis in recent researches
10
. Although at first there 
were several disadvantages of the medications – as 
INFα was available only in injectable form and the 
minimum treatment duration was 1 year of weekly 
injection with many side effects such as myalgia, 
asthenia, cytopenia, influenza-like symptoms and 
depression
11
 and RBV was accompanied by anemia
12
. 
As compared with other antiviral drugs, the 
encouraging results of the dual therapy with INFα and 
RBV persuaded the researchers to use interferon for 
several dose administration, treatment length and 
drugs combination trials to treat NANB hepatitis
13
. For 
the first time when RBV and INFα were used in 
combination for 24 weeks, the rate of SVR raised up 
Table 1: Guidelines for Dose Modification of Pegylated INFα-a2b and Ribavirin During Treatment of Chronically 
HCV-Infected. 
Laboratory values PEG-INF-a2b Ribavirin 
Hemoglobin 8.5-10.5 g/dL  Reduction to half the treatment 
dose 
 
Neutrophils  500-750/mm3 
Platelets 50,000-75,000/mm3 
Reduction to half the treatment dose  




Permanently discontinue  
 
Table 2: Socio-demographic characteristics of 
subjects. 




9.2 House hold 
Business 
5.1 unemployed 

















 Table 3: Selected Adverse Events Among Patients 
Treated With the Combination Therapy. 
percent Description 
23.5 Itching 
21.4 Cutaneous lesions 
5.1 Respiratory distress 
7.1 Nausea and vomiting 
6.2 distraction 
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to 34% and when the length of treatment exceeded to 
48 weeks, the rate of SVR increased even higher up 
to 42%
14,15
. Using today’s protocol in HCV 
combination therapy; patients revealed long-term 
prognosis, and it turned to be the earliest milestone in 
HCV treatment
4
. Nowadays, many new drugs have 








but as World Gastroenterology Organization 
mentioned in 2014, the dual therapy of PEG-IFNa2b 
and RBV for patients with HCV in resource-limited 
regions like our country is still recommending due to 
the high cost of new medications
19
. On the other 
hand, at that time we had faced restrictions to access 
these medications for treating our HCV infected 
patients due to goods and medication sanctions as 
well as poor patients’ economic status. 
Numerous studies have worked on the efficacy of 
dual therapy with pegylated INFα and RBV in the 
last decades and have confirmed sensible results for 
its use
20,21
. We had done a research to assess the real 
response to treatment in Iranian population. We 
found little drug related complications and an 
acceptable response of about 76.5%. In addition, We 
noted that, compared with the reports of the initial 
INFα -2b/RBV trials, our study had a greater number 
of dose modifications and fewer patients who 
discontinued therapy. This reality could explain the 
higher response rates compared with initial response 
to the standard treatment previously observed in 
large clinical trials (38–41%)
14,22
. Comparable rates 
of SVR were found in 75% of patients in Pakistan 
23
. 
This was higher than the response rate in a Canadian 
study (54%)
24
. Our results were also correlated with 
Naing and colleagues and Namazi et al. in terms of 
response to therapy
25,26
. Testing for HCV genotype is 
recommended to guide the selection of the most 
appropriate antiviral regimen
27
. Genotyping is useful 
in epidemiological studies and in clinical management 
for predicting the likelihood of response and 
determining the optimal duration of therapy as well
28
. 
The current study reported that genotype 1a and 3 
were the most prevalent. In a serological study on 
HCV-infected patients in Myanmar, 75% (18/24) were 
with genotype 3
29
. A faster progression of liver 
fibrosis in these patients was reported in empirical 
studies
30
; the high rate of SVR to the dual treatment in 
the present study has therefore resulted to more 
clinical benefits from reduction of liver-related 
morbidity and mortality. 
Identification of factors associated with positive HCV 
RNA level is critical to minimize prevalence and 
prevent adverse events and expense. Opiate use is still 
a very significant public health problem in Iran 
especially in its traditional form
31
. However, the most 
known risk factors for hepatitis C infection are 
addiction with injectable substances and blood 
transfusion from unknown donors
32
. Besides, our 
findings proved that the most common side effects in 
our patients were Myalgia, fatigue and malaises. It was 
similar to Hajaghmoradi in Iranian contexts
33
, but 
Yang reported Neutropinia and Juvendice as the most 
common prevalence of complications
34
. Our non-





Our results show that treatment with peg-IFN plus 
ribavirin is relatively well-responding in Iranian 
context. The rate of treatment discontinuation found in 
this study is low and side effects are tolerable. 
However, novel drug regimen is coming but dual 
therapy with the mentioned medication is reasonable 
to be the standard of therapy in our country according 
Table 4: Virologic response to the therapy. 
6 months after 
treatment 
48 weeks after 
treatment 
24 weeks after 
treatment 
12 weeks after 
treatment 
Time intervals 
76.5 81.6 79.6 69.4 SVR (%) 
 
Table 5: Change of lab parameters along the treatment. 
AST ALT PMN PT TSH Hg WBC Plat Variable 
0.001 0.001 0.008 0.006 0.13 0.084 0.007 0.006 P value 
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to the economic aspects. The short duration of 
therapy (6 months instead of 12) in patients with 
HCV can be the other contributed reason explaining 
this drugs as choice medication. 
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